Charles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Charles Schwab Investment Management Inc. lifted its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 43.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,645,787 shares of the company’s stock after buying an additional 498,417 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.56% of Lyell Immunopharma worth $1,053,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Centiva Capital LP bought a new position in shares of Lyell Immunopharma in the 3rd quarter valued at about $31,000. Intech Investment Management LLC acquired a new stake in Lyell Immunopharma in the 3rd quarter valued at about $52,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Lyell Immunopharma during the third quarter worth about $52,000. Erste Asset Management GmbH acquired a new position in Lyell Immunopharma during the third quarter worth approximately $82,000. Finally, SG Americas Securities LLC increased its position in Lyell Immunopharma by 102.8% during the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after buying an additional 59,182 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Lyell Immunopharma

In other Lyell Immunopharma news, CEO Lynn Seely bought 175,000 shares of the stock in a transaction dated Friday, March 14th. The shares were bought at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the acquisition, the chief executive officer now owns 712,500 shares of the company’s stock, valued at $434,625. This trade represents a 32.56 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Charles W. Newton purchased 200,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $0.56 per share, with a total value of $112,000.00. Following the completion of the purchase, the chief financial officer now owns 200,000 shares of the company’s stock, valued at $112,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 733,000 shares of company stock worth $429,550. Company insiders own 25.10% of the company’s stock.

Lyell Immunopharma Price Performance

NASDAQ:LYEL opened at $0.54 on Monday. The company has a market cap of $159.78 million, a P/E ratio of -0.69 and a beta of -0.41. The firm’s fifty day moving average price is $0.61 and its two-hundred day moving average price is $0.86. Lyell Immunopharma, Inc. has a one year low of $0.48 and a one year high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, equities research analysts expect that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.